<DOC>
	<DOCNO>NCT01707316</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( body medication ) pharmacodynamics ( action medication body ) JNJ-28431754 ( canagliflozin ) main metabolite ( break-down product ) follow 2 different dos canagliflozin healthy Chinese volunteer . Safety tolerability canagliflozin also assess .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Pharmacodynamics Canagliflozin Healthy Chinese Volunteers</brief_title>
	<detailed_description>This study double-blind ( neither Investigator volunteer know assign treatment ) , randomize ( treatment assign chance ) , placebo-controlled ( one study treatment inactive ) , single-dose , 3-way cross study ( volunteer receive 3 treatment different order ) healthy Chinese volunteer . Volunteers assign 1 3 treatment sequence group ( ABC , BCA , CAB ) . The treatment sequence decide randomization . Treatment A single oral ( mouth ) dose 100 mg canagliflozin . Treatment B single oral dose 300 mg canagliflozin . Treatment C single oral dose placebo ( inactive medication ) . Each treatment give treatment period 5 day duration ; treatment period separate washout period ( time period medication ) least 10 day . Canagliflozin currently investigate treatment type 2 diabetes mellitus ( T2DM ) .</detailed_description>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Volunteers must nonsmoker least 6 month first study drug administration Volunteers must consume 4 5 cup coffee tea 8 can cola day History currently active illness consider clinically significant Investigator illness Investigator considers exclude patient study could interfere interpretation study result Female volunteer breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>